Using RNA to interfere with a gene’s expression of disease-causing proteins is a validated therapeutic approach, but so far, the products in this drug class only address liver proteins. Reducing ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced changes to its Board of Directors, including the departure of two directors and the appointment of ...

SanegeneBio has formed a worldwide research and licensing partnership with Eli Lilly and Company to develop RNAi [RNA interference] candidates for metabolic diseases. These candidates will be ...

The milestone was earned when Arrowhead achieved the second development milestone event in a Phase 1/2 clinical study of ...

Through its innovative asymmetric siRNA platforms, OliX Pharmaceuticals is opening up huge opportunities in RNA interference-therapeutic development to address unmet needs for various indications ...

The Company expects to initiate first-in-human study in early 2026, with initial data anticipated H2 2026Clinical Trial Application (CTA) ...

In drug discovery, very little of what’s learned from one project can typically be carried over to the next. “For every new target you go after with a small molecule, you basically start from scratch, ...

A research team from the University of Cologne and collaborators has now shown that RNA interference, or RNAi for short, which is known to be a viral defense mechanism, also prevents the ...

Biopharmaceutical development efforts have been filled with many so-called promising technology platforms. Besides protein therapeutics, however, the challenges surrounding peptide- and ...

RNA interference (RNAi), discussed previously in The Scientist,1 is a post-transcriptional, targeted gene-silencing technique that uses double-stranded RNA (dsRNA) to degrade messenger RNA (mRNA) ...